Solna, Sweden, 28 March 2022 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that as of today, 28 March, its new name, Vivesto AB, has been registered with the Swedish Companies Registration Office. As a result of the name change, the company will also change the name and short name (ticker) of its share and paid subscribed shares (“BTA”).

The new name, Vivesto AB, which was approved at the Extraordinary General Meeting on 21 February 2022, reflects the company’s commitment to improve survival and quality of life for patients with cancer through investment in R&D and innovation and marks the end of a turn-around period for the company culminating in the recent successful financing which now provides ample funding for the future operations including key clinical trials.

François Martelet, CEO, said: “We are excited to start a new chapter for Vivesto with the recent completion of the rights issue, which created solid foundations that will enable us to continue to achieve our strategic goals by funding existing operations and clinical trials of our lead products in the next 18-24 months. We are now fully focused on making our ‘string of pearls’ strategy a reality by adding promising and innovative oncology programs to our pipeline through in-licensing and M&A. Our new identity encapsulates our mission to support life through a diversified portfolio of cancer therapies, and we have built a powerful platform for future growth.”

Change of name and short name (ticker)
The name of the share on Nasdaq Stockholm will change from Oasmia Pharmaceutical AB to Vivesto AB and its ticker from OASM to VIVE. The name of the BTA will change from Oasmia Pharmaceutical AB BTA to Vivesto AB BTA and its short name OASM BTA to VIVE BTA.

The ISIN code of the company’s share and BTA will remain unchanged. The last day for trading with the current tickers is today, 28 March 2022. The first day for trading with the new tickers will be on 29 March 2022.

This is an administrative matter. Shareholders therefore do not need to take any action.

The Company worked with the Brand Institute to develop its new identity. Vivesto was ranked highly for brand recognition and relevance by patients, medical professionals and investors surveyed in Europe, the US and Sweden.

For More Information: 

Vivesto AB
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 

Consilium Strategic Communications (For Vivesto)
Jonathan Birt, Ashley Tapp
Phone: +44 (0)20 3709 5700 

About Vivesto
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit